Sell into this rally... Here's why

By Bill Spencer ·

My mom turns 88 next month. That's quite an accomplishment, and a challenge.

She doesn't get around much and even moving from room to room in her home can be difficult. Not surprisingly, she does not want to move out of her house.

My sisters and I have been doing all we can to honor our mother's wish. We've retained cleaning services, landscapers and, especially, in-home healthcare specialists.

From where I'm standing, those people are heroes if not saints. They're friendly, professional and super-competent. And they don't come cheap.

If you're a "baby boomer" like me, you're sick of reading about how old your cohort is... How many of you retire every day... How few of you have enough saved for retirement...

And about how medically fragile you've become.

Nevertheless, the home care industry is growing at a rate of about +7% a year, making it one of the fastest-growing markets out there. By 2027, this market is forecast to reach $225.6 billion.

When we look at home care through the other end of the telescope, looking not at the very old (sorry Mom) but at the very young, the numbers are equally impressive.

U.S. Ped Homecare MarketSize

Between 2023 and 2033 the U.S. market for pediatric home healthcare will double in size, growing at a CAGR of +7.82%. Globally, that segment is expected to reach between $85.8 billion and $197 billion by 2033.

Aveanna Healthcare Holdings (AVAH) services both ends of the homecare market. This small-cap ($960 million) out of Atlanta, GA provides pediatric and adult healthcare services in the United States.

It offers a healthcare delivery platform that lets patients stay in their homes. At the same time, it frees up higher-cost care settings, such as hospitals for patients who must use them. That's a terrific add-on benefit to the community.

Not bad... A company that's doing well by doing good.

And Aveanna is doing very well indeed.

AVAH EPS

The company has grown its EPS on average by +55.75% in each of the past four quarters, and it's estimated that it will grow earnings by +125% in 2025.

Aveanna reported its second quarter results this past Thursday. For the quarter ending in June, AVAH reported revenue of $504.96 million. This was an increase of +7% over the same period last year. Its EPS came in at $0.01, compared to -$0.02 in the year-ago quarter.

Revenue beat estimates by 2.3% while EPS surpassed analyst estimates as well.

AVAH Beats

This is the second consecutive quarter that the firm has surprised to the upside. It has met or exceeded estimates for four quarters in a row.

Aveanna's CFO, Matt Buckhalter, told investors that, "Based on our positive results through the second quarter, we are raising our guidance to Revenue greater than $1,985 million and Adjusted EBITDA greater than $158 million. I am thrilled with the progress we've made on our business plans in delivering solid growth, great clinical outcomes, and improved profitability.”

Aveanna lives in Healthcare industry group, which is currently #1 out of 45 groups on our Sector Relative Strength Matrix.

Matrix

Since the market made a long-term bottom in late October, the Healthcare sector has spent a "healthy" amount of time in the top one-third of sector rankings.

HEAL History

We can see AVAH's technical attributes by running the ticker through our Portfolio Builder tool. (The Portfolio Builder, the Matrix and the Sector Ranking History indicator are all tools available on our Sector Prophets platform.)

AVAH Port

The blue arrow at the right tells us that the stock is outperforming the wider stock market. The first arrow shows us that the sector itself is outperforming the market as well.

I ran a performance screening, pitting AVAH against a basket of stocks that toil in a similar vineyard. They were: RadNet, Inc. (RDNT)... Addus HomeCare Corporation (ADUS)... DaVita Inc. (DVA)... Encompass Health Corporation (EHC)... and AdaptHealth Corp. (AHCO).

Here's the performance of those five stocks and AVAH over the past year. Aveanna is the red line.

AVAH Comps 1Yr

We see a similar outperformance when we narrow our focus to the past three months.

AVAH Comps 3Mos

Between mid-November (2023) and mid-July of this year, the stock traded within a horizontal channel between about $2.10 and $2.90 (the two green horizontal lines). It broke out of that channel on July 11th, and has gained almost +70%.

AVAH 1YrD

It made a new 52-week high this past Friday. The green arrows show how when the stock advances, trading volume gets heavy. On days when the price declines, volume is low. This shows us that buyers of the stock (the bulls) have enough capital and conviction to overpower the bears.

See the yellow highlighted region of the chart? After the stock broke out of that channel, it advanced as far as the dashed red line, then pulled back. What's interesting is that it never got as low as the upper channel line (a natural and expected support level). Instead, it bounced off the blue 50-day moving average line and headed higher.

The blue highlighted line at the upper right of the chart shows the 100% Fibonacci Extension level at $7.91. If the stock can reach that price, we'll have a return of about +60% from the current price.

One thing to notice about AVAH however. It's a volatile stock. Many small-caps are. With a beta of 2.09, the price will tend to move more than the general market. When the market advances, the stock will advance more. But when the market pulls back, the stock will pull back more.

We're still in the sweet spot of a long-term bull market. This stock should benefit. But (as we saw a few weeks ago) prices always retreat during bull markets. While this is a stock that can pay off handsomely, you'll likely need to ride out some scary dips.

Thanks for reading and I'll see you soon,

Bill Spencer
Editor-in-Chief, True Market Insiders